Literature DB >> 22516264

Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.

Bin Zhang1, Yin Wei Ho, Qin Huang, Takahiro Maeda, Allen Lin, Sung-Uk Lee, Alan Hair, Tessa L Holyoake, Claudia Huettner, Ravi Bhatia.   

Abstract

We characterized leukemia stem cells (LSC) in chronic phase chronic myelogenous leukemia (CML) using a transgenic mouse model. LSC were restricted to cells with long-term hematopoietic stem cell (LTHSC) phenotype. CML LTHSC demonstrated reduced homing and retention in the bone marrow (BM), related to decreased CXCL12 expression in CML BM, resulting from increased G-CSF production by leukemia cells. Altered cytokine expression in CML BM was associated with selective impairment of normal LTHSC growth and a growth advantage to CML LTHSC. Imatinib (IM) treatment partially corrected abnormalities in cytokine levels and LTHSC growth. These results were validated using human CML samples and provide improved understanding of microenvironmental regulation of normal and leukemic LTHSC and their response to IM in CML.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22516264      PMCID: PMC3332001          DOI: 10.1016/j.ccr.2012.02.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  42 in total

1.  HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta.

Authors:  Hui Peng; Nathan Erdmann; Nicholas Whitney; Huangyu Dou; Santhi Gorantla; Howard E Gendelman; Anuja Ghorpade; Jialin Zheng
Journal:  Glia       Date:  2006-11-01       Impact factor: 7.452

2.  Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

Authors:  Daniela S Krause; Katherine Lazarides; Ulrich H von Andrian; Richard A Van Etten
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

Review 3.  Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.

Authors:  Jorge Cortes; Andreas Hochhaus; Timothy Hughes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

4.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

Authors:  Jean-Claude Chomel; Marie-Laure Bonnet; Nathalie Sorel; Angelina Bertrand; Marie-Claude Meunier; Serge Fichelson; Michael Melkus; Annelise Bennaceur-Griscelli; François Guilhot; Ali G Turhan
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

5.  High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations.

Authors:  C T Jordan; G Yamasaki; D Minamoto
Journal:  Exp Hematol       Date:  1996-09       Impact factor: 3.084

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia.

Authors:  A L Petzer; C J Eaves; P M Lansdorp; L Ponchio; M J Barnett; A C Eaves
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

8.  Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

Authors:  W S Pear; J P Miller; L Xu; J C Pui; B Soffer; R C Quackenbush; A M Pendergast; R Bronson; J C Aster; M L Scott; D Baltimore
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

9.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

10.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

View more
  166 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  The hematopoietic stem cell niche in homeostasis and disease.

Authors:  Laura M Calvi; Daniel C Link
Journal:  Blood       Date:  2015-10-14       Impact factor: 22.113

Review 3.  The aging hematopoietic stem cell niche: Phenotypic and functional changes and mechanisms that contribute to hematopoietic aging.

Authors:  Sarah E Latchney; Laura M Calvi
Journal:  Semin Hematol       Date:  2016-10-19       Impact factor: 3.851

4.  A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia.

Authors:  Ninib Baryawno; Dariusz Przybylski; Monika S Kowalczyk; Youmna Kfoury; Nicolas Severe; Karin Gustafsson; Konstantinos D Kokkaliaris; Francois Mercier; Marcin Tabaka; Matan Hofree; Danielle Dionne; Ani Papazian; Dongjun Lee; Orr Ashenberg; Ayshwarya Subramanian; Eeshit Dhaval Vaishnav; Orit Rozenblatt-Rosen; Aviv Regev; David T Scadden
Journal:  Cell       Date:  2019-05-23       Impact factor: 41.582

5.  Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.

Authors:  Xiaoyan Zhang; Huaijun Tu; Yazhi Yang; Xiaoyan Jiang; Xianliang Hu; Qidong Luo; Jian Li
Journal:  J Biol Chem       Date:  2019-06-24       Impact factor: 5.157

6.  Chronic myeloid leukemia stem cells require cell-autonomous pleiotrophin signaling.

Authors:  Heather A Himburg; Martina Roos; Tiancheng Fang; Yurun Zhang; Christina M Termini; Lauren Schlussel; Mindy Kim; Amara Pang; Jenny Kan; Liman Zhao; Hyung Suh; Joshua P Sasine; Gopal Sapparapu; Peter M Bowers; Gary Schiller; John P Chute
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 7.  Neural regulation of hematopoiesis, inflammation, and cancer.

Authors:  Maher Hanoun; Maria Maryanovich; Anna Arnal-Estapé; Paul S Frenette
Journal:  Neuron       Date:  2015-04-22       Impact factor: 17.173

Review 8.  Extrinsic regulation of hematopoietic stem cells in development, homeostasis and diseases.

Authors:  Yeojin Lee; Matthew Decker; Heather Lee; Lei Ding
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2017-05-31       Impact factor: 5.814

Review 9.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

10.  Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.

Authors:  Christopher A Eide; Matthew S Zabriskie; Samantha L Savage Stevens; Orlando Antelope; Nadeem A Vellore; Hein Than; Anna Reister Schultz; Phillip Clair; Amber D Bowler; Anthony D Pomicter; Dongqing Yan; Anna V Senina; Wang Qiang; Todd W Kelley; Philippe Szankasi; Michael C Heinrich; Jeffrey W Tyner; Delphine Rea; Jean-Michel Cayuela; Dong-Wook Kim; Cristina E Tognon; Thomas O'Hare; Brian J Druker; Michael W Deininger
Journal:  Cancer Cell       Date:  2019-09-19       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.